Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Univariate analysis: Influence on TTP (second-line)

From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Factor Median TTP (months) 95% CI SE* p =
Age > 65 years 6 vs. 7 0.00-12.79 3.36 n.s.
   5.64-8.36 0.7  
Age < 35 years 3 vs. 7 0.23-5.77 1.41 0.026
   5.67-8.33 0.68  
Stage 4 at diagnosis 6 vs. 7 5.52-8.48 0.76 n.s.
   0.39-11.61 2.86  
Grading (1,2 versus 3) 6 vs. 7 2.98-9.03 1.54 n.s.
   5.6-8.41 0.72  
Histologic type (ductal versus lobular) 6 vs. 9 4.86-7.14 0.58 n.s.
   0.71-17.29 4.23  
Positive hormone receptor status 6 vs. 7 4.64-7.36 0.7 n.s.
   5.14-8.86 0.95  
Time to recurrence < 12 months 6 vs. 7 3.41-8.59 1.32 n.s.
   5.61-8.39 0.71  
Visceral metastases 7 vs. 6 5.76-8.25 0.64 n.s.
   0.00-12.53 3.33  
Number of metastatic sites (1 versus 2) 14 vs. 6 9.56-18.44 2.26 0.013
   5.02-6.98 0.5  
Number of metastatic sites (2 versus > 2) 8 vs. 6 5.58-10.42 1.23 0.003
   5.09-6.91 0.47  
Trastuzumab from first-line palliative treatment 7 vs. 6 5.62-8.38 0.71 n.s.
   4.65-7.35 0.69  
Response to first-line trastuzumab-based therapy 7 vs. 6 5.25-8.75 0.89 n.s.
   3.77-8.23 1.14  
New metastatic sites at progression upon first-line trastuzumab-based therapy 7 vs. 6 4.81-9.19 1.12 n.s.
   5.12-6.88 0.45  
  1. * SE: Standard error